- ►ieo.it [PDF] F Bertolini, P Mancuso, Y Shaked, RS Kerbel - Drug Discovery Today, 2007 - Elsevier Medical oncologists are increasingly using anti-angiogenic drugs, but
identifying the best-suited drug and the optimal dosage and schedule for
treatment of patients remain challenging issues. Circulating endothelial ... Cited by 27 - Related articles - All 4 versions
- ►prsjournal.com M Soheilian, A Ramezani, B Bijanzadeh, M … - Retina, 2007 - journals.lww.com From the *Ophthalmology Department and Ophthalmic Research Center, Labbafinejad
Medical Center, Shaheed Beheshti Medical University, Tehran, Iran; †Negah Eye
Hospital, Tehran, Iran; and the ‡Department of Ophthalmology, University ... Cited by 23 - Related articles - BL Direct - All 6 versions
- ►iovs.org H Ameri, GJ Chader, JG Kim, SVR Sadda, … - Investigative Ophthalmology & Visual Science, 2007 - ARVO METHODS. Twenty-four rabbits were divided into five groups. Group A included
four rabbits; all other groups included five rabbits each. Group A received
intravitreous VEGF only, and group E received intravitreous bevacizumab ... Cited by 13 - Related articles - BL Direct - All 3 versions
H Quiroz-Mercado, O Ustariz-González, MA … - Seminars in Ophthalmology, 2007 - informahealthcare.com This retrospective report describes our 20 months'experience using intravitreal
injections of bevacizumab for the treatment of several retinal diseases. We
describe our experience after 1765 intravitreal injections of bevacizumab ... Cited by 14 - Related articles - BL Direct - All 6 versions
MS Ip, IU Scott, GC Brown, MM Brown, AC Ho … - Ophthalmology, 2008 - Elsevier Literature searches were conducted in May and October 2007 in PubMed with no
date restrictions, limited to articles published in English, and in the Cochrane
Central Register of Controlled Trials without a language limitation and ... Cited by 13 - Related articles - All 5 versions
S Roy, S Khanna, CK Sen - Free Radical Biology and Medicine, 2008 - Elsevier Vascularization, under physiological or pathophysiological conditions, typically
takes place by one or more of the following processes: angiogenesis,
vasculogenesis, arteriogenesis, and lymphangiogenesis. Although all of ... Cited by 7 - Related articles - All 3 versions
- ►prsjournal.com LJ Hernandez-Pastor, A Ortega, A Garcia- … - American Journal of Health-System Pharmacy, 2008 - pt.wkhealth.com LUIS JAVIER HERNANDEZ-PASTOR, PHARM D., is Resident, Pharmacy Department,
University Clinic; ANA ORTEGA, PHARM.D., PH.D., is Consultant Pharmacist,
Clinica Universitaria, and Assistant Professor, Faculty of Pharmacy; ... Cited by 5 - Related articles - All 8 versions
H Hasegawa, K Sode, K Ikebukuro - Biotechnology Letters, 2008 - Springer Abstract Two DNA aptamers against a tumor marker protein, human vascular
endothelial growth factor (VEGF165) were identified. In the screening process,
another protein was used as the competitor to isolate those aptamers that ... Cited by 5 - Related articles - BL Direct - All 6 versions
J Ruys, JJ De Laey, Y Vanderhaeghen, EH … - Eye, 2007 - nature.com Jump to main content; Jump to navigation; nature.com homepage; Publications AZ index;
Browse by subject. My account; Submit manuscript; Register; Subscribe; RCOphth ... Cited by 4 - Related articles - BL Direct - All 3 versions
